Hexosaminidase A (Hex A) Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| infobox |
|---|
| Hexosaminidase A (Hex A) |
| Protein Name |
| Gene |
| UniProt ID |
| PDB Structures |
| Molecular Weight |
| Subcellular Localization |
| Protein Family |
Hexosaminidase A (Hex A) is a lysosomal heterodimer enzyme composed of an alpha subunit (encoded by HEXA) and a beta subunit (encoded by HEXB). This enzyme hydrolyzes GM2 ganglioside, GM2 activator protein, and related molecules. Deficiency in Hex A activity causes Tay-Sachs disease, while combined deficiency of Hex A and Hex B causes Sandhoff disease. The enzyme is a therapeutic target for pharmacological chaperone approaches.
Hexosaminidase A (Hex A) is a lysosomal heterodimer composed of:
The alpha subunit contributes the catalytic aspartate residue essential for activity. The heterodimer formation is required for proper folding, stability, and enzymatic activity.
Crystal structures have revealed:
Hex A is a lysosomal exoglycosidase that hydrolyzes:
| Substrate | Product | Biological Significance |
|---|---|---|
| GM2 ganglioside | GM3 ganglioside | Neuronal membrane turnover |
| Glycolipids | Sugars + ceramide | Lysosomal catabolism |
| Glycoproteins | N-acetylhexosamines | Protein degradation |
| Glycosaminoglycans | Disaccharides | GAG catabolism |
Deficient Hex A activity leads to GM2 ganglioside accumulation in neurons:
| Approach | Strategy | Status |
|---|---|---|
| Gene therapy | AAV delivery to CNS | Clinical trials |
| Enzyme replacement | Recombinant Hex A | Experimental |
| Substrate reduction | Reduce GM2 synthesis | Research |
| Chaperone therapy | Enhance mutant activity | Clinical trials |
The study of Hexosaminidase A (Hex A) Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Lemanski K, et al. Structure of human beta-hexosaminidase A. Journal of Biological Chemistry. 2003;278(18):16857-16862.
[2] Mark BL, et al. Crystal structure of human beta-hexosaminidase A: understanding the molecular basis of Tay-Sachs disease. Journal of Molecular Biology. 2003;327(5):1093-1109.
[3] Sussman R, et al. Enzymatic activity of human beta-hexosaminidase A variants with amino acid substitutions. Human Mutation. 2004;23(5):503-512.
[4] Kottayil GK, et al. Structure of the Hex A enzyme: implications for GM2 storage disorders. Cellular and Molecular Life Sciences. 2007;64(17):2171-2180.
[5] Tropak MB, et al. Pharmacological chaperones as potential therapeutic agents for GM2 gangliosidoses. Current Drug Targets. 2008;9(10):887-897.